Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04280822 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma

StatusRecruiting
PhasePhase 3
Started2020-04-21
View on ClinicalTrials.gov ↗
Record status
This record was last updated October 4, 2022 (before its estimated December 2, 2023 completion). Its status may not reflect the trial's current state.

Amendment history

2022-10-02
Study Status v2
Re-verified, no change to tracked fields
2020-05-11
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2020-03-02→confirmed 2020-04-21
Study sitesdetails revised at 1 of 1 site
2020-02-20
Original filing
The effect of neo-adjuvant immunochemotherapy on survival of patients with thoracic esophageal squamous cell carcinomas remains unknown. One of our objectives is to evaluate whether the neo-adjuvant immunochemotherapy Toripalimab (JS001) with cisplatin and paclitaxel followed by right thoracic approach esophagectomy with total 2-field lymph node dissection improves the overall survival of thoracic esophageal cancer patients versus neo-adjuvant chemotherapy.
Trial Details
NCT Number NCT04280822
Lead Sponsor Henan Cancer Hospital
Conditions Esophageal Cancer, Surgery, Neoadjuvant Treatment, Survival
Enrollment 400 participants
Start Date 2020-04-21
Primary Completion 2023-12-02 (estimated)
Study Completion 2028-03-02 (estimated)
Updated on ClinicalTrials.gov 2022-10-04